Journal Ad

AMA to shutter newspaper amid ad turmoil

AMA to shutter newspaper amid ad turmoil

By

American Medical News' 55-year publishing run will come to a close this year, the AMA, its publisher, said today.

Mobile ads rank low in physician recall study

By

CMI/Compas says mobile-ad recall is low but growing, and that smartphones rule professional mobile use.

Big publishers back startup's journal "sneak-peek" service

Big publishers back startup's journal "sneak-peek" service

By

Publisher middleman DeepDyve has launched a five-minute "freemium" service that CEO William Park says saves researchers money, and prevents the hassle of buying off-target research. Publishers such as Wiley support the service through cross-promotions on their websites.

Pradaxa dominates doc poll of most effective journal ads

Pradaxa dominates doc poll of most effective journal ads

By

The most effective journal ads of the year included executions for Pradaxa, Humira and Conceptus' Essure Procedure, according to the Doctors' Choice Study.

Medical Advertising Hall of Fame inducts three

By

Medscape founder Peter Frishauf, advertising metrics pioneer David Labson and Dorothy Philips, Ph.D., who blazed a trail for women in medical advertising, are MAHF's newest inductees.

New ad model fosters pharma's leap to digital, publisher finds

New ad model fosters pharma's leap to digital, publisher finds

By

Statistics show medical professionals are migrating toward iPads. Now, one medical journal publisher says, advertisers have followed.

How Genentech cut journal ads across all Avastin indications

How Genentech cut journal ads across all Avastin indications

By

Well before the FDA revoked Avastin's approval in breast cancer, Roche's Genentech unit deeply cut the professional media plan for the drug, the company said.

Majority of pharma journal ads not FDA-compliant: study

By

Four out of five ads analyzed in a study of physician-directed pharmaceutical advertising would definitely not pass FDA muster, or might have trouble doing so, said researchers. Their findings may have implications for the FDA, DDMAC and the "Bad Ad" program.

Ad for platelet-inhibition test pushes envelope, cardiologist asserts

Ad for platelet-inhibition test pushes envelope, cardiologist asserts

By

Is a medical journal ad for platelet-inhibition testing backed up by evidence that treatment guided by such testing can reduce the risk of clot formation?

AMM reveals Doctors' Choice Awards finalists

AMM reveals Doctors' Choice Awards finalists

By

In what could be seen as a positive sign of the times, the Association of Medical Media (AMM) announced the finalists for its 2010 Doctors' Choice Awards, which recognizes the best pharmaceutical journal ads, as chosen by physicians. The AMM established the awards in 2003, but did not give the awards last year, due to budgetary concerns.

Two-for-one: Quadrant pairs journal titles for advertisers

Two-for-one: Quadrant pairs journal titles for advertisers

By

Quadrant HealthCom united two titles - The Female Patient and OBG Management - under an alliance providing advertisers with a "ping-pong" opportunity for campaigns.

Sage upgrades online journal platform

Sage upgrades online journal platform

By

Sage, an international publisher of medical journals, books and electronic media, is shifting all of its 560-plus titles onto a new platform hosted by Stanford University Libraries' HighWire Press.

Healthy Advice to mount flat screens in doc's offices

Healthy Advice to mount flat screens in doc's offices

By

Healthy Advice Networks is betting docs need one more video screen to look at during office hours.

UK journal ad spins weight gain side effect

UK journal ad spins weight gain side effect

By

UK regulators vowed to investigate a medical journal ad for AstraZeneca's Seroquel that allegedly minimized weight gain data, a common side effect associated with atypical anti-psychotic drugs.

DDMAC cites fishy Cymbalta fibromyalgia ads

DDMAC cites fishy Cymbalta fibromyalgia ads

By

The FDA issued an untitled letter upbraiding Lilly for Cymbalta consumer and professional ads.

Cephalon consolidates oncology professional into Draftfcb

By

Cephalon has consolidated its oncology advertising business into Interpublic Group's Draftfcb.

Quadrant HealthCom buys Dowden journals

By

Quadrant HealthCom purchased the journals division of Dowden Health Media from Lebhar-Friedman. Terms of the deal were not disclosed.

Frank Corbett, medical advertising great, dies

Frank Corbett, medical advertising great, dies

By

Medical advertising pioneer Frank J. Corbett, a founder of the Corbett Accel network, passed away at the age of 92.

King's all kid gloves on Embeda launch

King's all kid gloves on Embeda launch

By

King's launch of Embeda, a pain drug containing morphine, demonstrates that even supposedly abuse-resistant narcotic products need to take a careful approach in their marketing.

DDMAC slaps J&J journal ad, Pedinol mailer

DDMAC slaps J&J journal ad, Pedinol mailer

By

The FDA issued an untitled letter to J&J for a journal ad for its athlete's foot treatment Ertaczo Cream, saying the ad omits key risk info, broadens the indication and overhypes efficacy.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.